BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20716806)

  • 41. Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches.
    Atreya CE; Yaeger R; Chu E
    Am Soc Clin Oncol Educ Book; 2017; 37():246-256. PubMed ID: 28561718
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies.
    Hawkes E; Cunningham D
    J Clin Oncol; 2010 Oct; 28(28):e529-31; author reply e532-e533. PubMed ID: 20679615
    [No Abstract]   [Full Text] [Related]  

  • 43. Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
    Igarashi H; Kurihara H; Mitsuhashi K; Ito M; Okuda H; Kanno S; Naito T; Yoshii S; Takahashi H; Kusumi T; Hasegawa T; Sukawa Y; Adachi Y; Okita K; Hirata K; Imamura Y; Baba Y; Imai K; Suzuki H; Yamamoto H; Nosho K; Shinomura Y
    Ann Surg Oncol; 2015 Aug; 22(8):2640-8. PubMed ID: 25472647
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
    Bardelli A; Siena S
    J Clin Oncol; 2010 Mar; 28(7):1254-61. PubMed ID: 20100961
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacoproteomic characterisation of human colon and rectal cancer.
    Frejno M; Zenezini Chiozzi R; Wilhelm M; Koch H; Zheng R; Klaeger S; Ruprecht B; Meng C; Kramer K; Jarzab A; Heinzlmeir S; Johnstone E; Domingo E; Kerr D; Jesinghaus M; Slotta-Huspenina J; Weichert W; Knapp S; Feller SM; Kuster B
    Mol Syst Biol; 2017 Nov; 13(11):951. PubMed ID: 29101300
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
    Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
    BMC Cancer; 2019 May; 19(1):421. PubMed ID: 31060539
    [TBL] [Abstract][Full Text] [Related]  

  • 47. RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy.
    Mini E; Lapucci A; Perrone G; D'Aurizio R; Napoli C; Brugia M; Landini I; Tassi R; Picariello L; Simi L; Mancini I; Messerini L; Magi A; Pinzani P; Mazzei T; Tonelli F; Nobili S
    Int J Cancer; 2019 Nov; 145(9):2580-2593. PubMed ID: 30973654
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update.
    Baraibar I; Ros J; Mulet N; Salvà F; Argilés G; Martini G; Cuadra JL; Sardo E; Ciardiello D; Tabernero J; Élez E
    Expert Rev Mol Diagn; 2020 Jul; 20(7):653-664. PubMed ID: 32552041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
    Saridaki Z; Georgoulias V; Souglakos J
    World J Gastroenterol; 2010 Mar; 16(10):1177-87. PubMed ID: 20222160
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision.
    Rebersek M
    Radiol Oncol; 2020 May; 54(3):272-277. PubMed ID: 32463385
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer.
    Baek SK; Lee KT; Bae SB; Lee SC
    Korean J Intern Med; 2019 Nov; 34(6):1188-1196. PubMed ID: 31346151
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacogenomics and -genetics in colorectal cancer.
    Pohl A; Lurje G; Manegold PC; Lenz HJ
    Adv Drug Deliv Rev; 2009 May; 61(5):375-80. PubMed ID: 19100300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.
    Sepulveda AR; Hamilton SR; Allegra CJ; Grody W; Cushman-Vokoun AM; Funkhouser WK; Kopetz SE; Lieu C; Lindor NM; Minsky BD; Monzon FA; Sargent DJ; Singh VM; Willis J; Clark J; Colasacco C; Rumble RB; Temple-Smolkin R; Ventura CB; Nowak JA
    J Clin Oncol; 2017 May; 35(13):1453-1486. PubMed ID: 28165299
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolomics for biomarker discovery in the diagnosis, prognosis, survival and recurrence of colorectal cancer: a systematic review.
    Zhang F; Zhang Y; Zhao W; Deng K; Wang Z; Yang C; Ma L; Openkova MS; Hou Y; Li K
    Oncotarget; 2017 May; 8(21):35460-35472. PubMed ID: 28389626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
    Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J
    J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management.
    Lieu CH; Corcoran RB; Overman MJ
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():207-215. PubMed ID: 31099678
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options.
    Rodrigues D; Longatto-Filho A; Martins SF
    Biomed Res Int; 2016; 2016():6896024. PubMed ID: 27563673
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.
    Lech G; Słotwiński R; Słodkowski M; Krasnodębski IW
    World J Gastroenterol; 2016 Feb; 22(5):1745-55. PubMed ID: 26855534
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.
    Zhuang Y; Wang H; Jiang D; Li Y; Feng L; Tian C; Pu M; Wang X; Zhang J; Hu Y; Liu P
    BMC Cancer; 2021 Apr; 21(1):380. PubMed ID: 33836681
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer.
    Nguyen MN; Choi TG; Nguyen DT; Kim JH; Jo YH; Shahid M; Akter S; Aryal SN; Yoo JY; Ahn YJ; Cho KM; Lee JS; Choe W; Kang I; Ha J; Kim SS
    Oncotarget; 2015 Oct; 6(31):31674-92. PubMed ID: 26397224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.